



Heather Cook, PharmD¹; Kathryn Walker², PharmD; Nicole Graham, PharmD⁴; Jacob Radcliff, PharmD⁴; Diana Stewart, PharmD⁴; Maria Lowry, PharmD¹ 1. MedStar Union Memorial Hospital; 2. MedStar Health; 3. MedStar Good Samaritan Hospital; 4. MedStar Washington Hospital Center

Introduction

- Palliative care pharmacists are essential palliative care team members. In addition to contributing to the holistic care of the patient, they are uniquely focused on optimizing medication use. Deprescribing is often an important part of aligning medications with goals of care.
- Deprescribing is the process of withdrawal of an inappropriate medication, supervised by a health care professional with the goal of managing polypharmacy and improving outcomes.²
- One study showed 78% of pharmacist-initiated deprescribing recommendations accepted by physicians. Most cited reasons include over-duration of treatment, unclear indication, and overdosage.³

Primary Outcome

 Quantify acceptance rates of PC pharmacists' recommendations

Secondary Outcome

- Evaluate deprescribing interventions including:
- Common medication classes
- Reasons for discontinuation
- Patient/family understanding & acceptance

Methods


- Retrospective study approved by MHRI IRB and conducted February-May 2019 – May 1, 2019
- Patient Selection: patients receiving PC pharmacist evaluation for deprescribing as part of a comprehensive PC consultation
- MedStar Hospital Sites:
 - Medstar Union Memorial Hospital (MUMH)
 - Medstar Good Samaritan Hospital (MGSH)
 - Medstar Washington Hospital Center (MWHC)
- <u>Data collection</u>: data elements related to deprescribing collected at point of care and entered into collaborative spreadsheet (Cerner powerform created for future data collection)

Inclusion Criteria	Exclusion Criteria
 Age ≥ 18 years 	 Compassionate extubation
 Received PC consult 	 Patients who left against
including PC pharmacist at	medical advice
selected Medstar sites	


Let it Go! Clinical pharmacists in palliative care: Impact on deprescribing

Results

Baseline Characte	eristic	(n=49)	
Age - mean <u>+</u> SD, yrs	76.2 ±12.6		$\widehat{}$
Female, % (n)		67% (33)	1/210)
Setting			=17.
Inpatient, % (n)		92% (45)	D C C C
Outpatient, % (n)		8% (4)	an tar
Disposition Location Hospice, % (n)		63% (31)	e
Non-hospice, % (n)		37% (18)	ary
Site			Prime
MUMH, % (n)		59% (29)	
MGSH, % (n)		29% (14)	
MWHC, % (n)		12% (6)	
Outcom	nes		
Total # patients		49	
Total # recommendations		210	100
Total recommendations bas indication (188 of 210):	ed on	type of	
Primary Indication		43% (81)	
Secondary Indicatio	n	30% (56)	
Tertiary Indication		27% (51)	
Total recommendations bas assessed by pharmacists (1		• •	
High Priority		37% (72)	Antibiotics (n=
Low Priority		63% (122)	100
Recommendations accept by primary team	ted	81% (171)	Lim
Clinician Perceived Patient/Caregiver		cian Perceived ent/Caregiver	• Re
Understanding (n=125)	Acce	eptance (n=129)	Con
			• Giv illn
			Refe
93%		91%	1. Natio
			2018 2. Reev
Fully Partially	■ Full	y Partially	2. Reev Phari 3. Chec 25(e ²



% Acceptance of Medication Classes* (n=210 recommendations)



itations

trospective study, small sample size, did not reach target # of patients

clusion

ven the high acceptance rate of deprescribing recommendations, PC Pharmacists can greatly impact patients with serious less by routinely evaluating risks vs. benefits of medications to align with patient's goals.


erences

ional Consensus Project for Quality Palliative Care. Clinical Practice Guidelines for Quality Palliative Care, 4th edition. Richmond, VA: National Coalition for Hospice and Palliative Care; 8. https://www.nationalcoalitionhpc.org/ncp. eve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of 'deprescribing' with network analysis: implications for future research and clinical practice. Br J Clin armacol. 2015 Dec; 80(6):1254-68. eong ST, Ng TM, Tan KT. Pharmacist-initiated deprescribing in hospitalised elderly: prevalence and acceptance by physicians. European Journal of Hospital Pharmacy. 2018 Mar 25(e1):e35–9.

Reason for Discontinuation

(n=210 recommendations)

Decrease pill burden Unacceptable treatment burden Potential harm> benefit Patient/caregiver preference Lack of data to support benefit Lack of time to benefit Lack of adherence No clear indication Patient experienced harm = 10 Condition changed **7** Changed to alternative med **7** Duplicate therapy 2 Unacceptable financial burden 1



*Categories with 0 results were omitted: antipsychotic, anxiolytic, bisphosphonate, NSAID, oncology agents